The acquisition marks Samsung Biologics’ geographical diversification, establishing its first US manufacturing presence and expanding regional client support.
Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.
